We present (see the Table) our meta-analyses of the effects of antiplatelet regimens on the end point of stroke in long-term secondary stroke prevention trials (CAPRIE 1 and AAASPS 2 ; references for all other trials are in antiplatelet trialist articles 3,4 ). Statistically significant results are indicated by their 95% confidence intervals (CI). That aspirin (ASA) is better than placebo is well demonstrated statistically (PϽ0.001), but the benefit is modest: a relative risk reduction (RRR) of 16%. The benefit from dipyridamole (DP) monotherapy appears to be similar to that of ASA. The ADP receptor antagonists (ADPRAs) clopidogrel and ticlopidine are perhaps somewhat more effective than ASA (estimate, 8%), but the differences are not statistically significant. Furthermore, there are serious safety concerns with ticlopidine.
through different mechanisms are superior to any single agent alone, or pairs of agents, in modifying platelet activity and heterotypic cell adhesion and leukocyte activation. Combining three different antiplatelet agents may be a new mechanistic strategy for antiplatelet therapy, specifically in the secondary prevention of vascular disease."
Based on the observed mean RR for DP plus ASA versus ASA (0.796; 95% CI, 0.676 to 0.939), on the assumption that ADPRA effects and DPϩASA effects are independent, and on the conservative estimate that ADPRA and ASA effects are equal, ie, they each reduce risk by 16% (RRRϭ0.838) versus placebo, the projection of RR for the combination DPϩASAϩADPRA versus ASA is 0.796ϫ0.838ϭ0.667, for an RRR of 33%. The projection of RR for the combination DPϩASAϩADPRA versus placebo is 0.652ϫ0.838ϭ0.546, for an RRR of 45%.
Thus, triple therapy might improve the best current RRR for stroke from 35% against placebo to (an estimated mean value of) 45% versus placebo. This potential for improvement in prophylaxis warrants a clinical trial.
In conclusion, dual therapy with DP and ASA (not monotherapy with any antiplatelet agent) should be the standard regimen for the individual patient who has had transient ischemic attack or ischemic stroke of noncardiac origin and is the only currently acceptable control regimen in clinical trials. Triple therapy with DPϩASAϩADPRA projects as superior to DPϩASA dual therapy; a trial of triple versus dual therapy is warranted. *For all but 2 trials the endpoint is Any Stroke: any ischemic stroke, intracranial hemorrhage, or stroke of uncertain mechanism. In the CAPRIE report, the only outcome data for the stroke secondary prevention subgroup are for ischemic stroke. For the Japanese B study, only nonfatal stroke outcome data are available.
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†The studies selected were long-term prophylactic trials (not 2-to 4-week studies after acute stroke) in which antiplatelet regimens were tested against other antiplatelet regimens or against placebo in people who had had TIA or ischemic stroke not of cardiac origin.
‡Aspirin 50 -1500 mg. The studies were AICLA, AITIA, Canadian cooperative, Danish cooperative, ESPS2, Reuther, SALT, Britton (Swedish cooperative study), and UK-TIA.
§Dipyridamole 400 -800 mg vs placebo; data from ESPS2, Stoke. ʈDipyridamole 400 mg vs aspirin 50 mg; data from ESPS2. ¶Dipyridamole 225-400 mg plus aspirin 50 -1300 mg vs placebo; data from AICLA, ESPS1 and 2. # Dipyridamole 225-400 mg plus aspirin 50 -1300 mg vs ASA 50 -1300 mg; data from ACCSG, AICLA, ESPS2. **Clopidogrel 75 mg vs ASA 325 mg; data from CAPRIE. † †Ticlopidine 200 -500 mg vs ASA 500 -1300 mg; data from AAASPS, Japanese B, TASS.
